

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb30428</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Monoclonal Antibody Against ROR1 Induces Apoptosis in Human Bladder Carcinoma Cells</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Bayat </surname><given-names>Ali Ahmad</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sadeghi</surname><given-names>Niloufar</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Fatemi</surname><given-names>Ramina</given-names></name></contrib><aff>Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Nowroozi</surname><given-names>Mohammad Reza</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Ohadian Moghadam</surname><given-names>Solmaz</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Borzuee</surname><given-names>Mohadeseh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Radmanesh</surname><given-names>Amin</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Khodadoost</surname><given-names>Mahmood</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sarrafzadeh</surname><given-names>Ali reza</given-names></name></contrib><aff>Department of Medical Genetics, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Zarei</surname><given-names>Omid</given-names></name></contrib><aff>Department of Biochemistry, Science and Research Branch, Islamic Azad University      , Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rabbani</surname><given-names>Hodjattallah</given-names></name></contrib><aff>Immune and Gene Therapy Laboratory, CCK, Karolinska University Hospital Solna      , Stockholm, Sweden</aff><aff>Department of Antigen and Antibody Engineering, Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR      , Tehran, Iran</aff></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>12</volume>
      <issue>3</issue>
      <fpage>165</fpage>
      <lpage>171</lpage>
      <history>
        <date date-type="received">
          <day>9</day>
          <month>11</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>3</month>
          <year>2020</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;&lt;span style=&quot;font-size:10pt&quot;&gt;Background: Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) is one of the promising cell surface antigens for targeting cancer cells. The aim of this study was to evaluate ROR1 cell surface expression in bladder cancer cells using a murine anti-ROR1 monoclonal antibody (mAb) called 5F1-B10 as well as investigate its potential in apoptosis induction.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:10pt&quot;&gt;Methods: Expression of ROR1 in two human bladder cell lines, 5637 and EJ138, as well as a non-cancerous human cell line, Human Fetal Foreskin Fibroblast (HFFF), was examined by flow cytometry and immunocytochemistry. Immunohistochemical staining of cancer and normal bladder tissues was also performed.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:10pt&quot;&gt;Results: The flow cytometry results showed that 5F1-B10 mAb could recognize ROR1 molecules in 86.1% and 45.6% of 5637 and EJ138 cells, respectively. The expression level of ROR1 was 5.49% in HFFF cells. The immunocytochemistry and immunohistochemistry staining results also confirmed the presence of ROR1 on the surface of both bladder cancer cells and tissues, respectively. The obtained data from apoptosis assay demonstrated that 5F1-B10 mAb could induce apoptosis in both 5637 and EJ138 cell lines.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:10pt&quot;&gt;Conclusion: Taken together, our finding indicates the role of ROR1 in bladder cancer cell survival and suggests this receptor might be a promising target for developing novel therapeutic agents against bladder carcinoma.&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
